United Therapeutics Corporation
UTHR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,877 | $2,328 | $1,936 | $1,686 |
| % Growth | 23.6% | 20.2% | 14.9% | – |
| Cost of Goods Sold | $310 | $258 | $147 | $123 |
| Gross Profit | $2,568 | $2,070 | $1,790 | $1,563 |
| % Margin | 89.2% | 88.9% | 92.4% | 92.7% |
| R&D Expenses | $481 | $408 | $323 | $540 |
| G&A Expenses | $542 | $395 | $416 | $403 |
| SG&A Expenses | $639 | $477 | $487 | $467 |
| Sales & Mktg Exp. | $96 | $82 | $71 | $64 |
| Other Operating Expenses | $71 | $0 | $0 | $0 |
| Operating Expenses | $1,191 | $885 | $810 | $1,007 |
| Operating Income | $1,377 | $1,185 | $980 | $556 |
| % Margin | 47.9% | 50.9% | 50.6% | 33% |
| Other Income/Exp. Net | $162 | $89 | -$29 | $38 |
| Pre-Tax Income | $1,539 | $1,274 | $951 | $594 |
| Tax Expense | $344 | $290 | $223 | $118 |
| Net Income | $1,195 | $985 | $727 | $476 |
| % Margin | 41.5% | 42.3% | 37.6% | 28.2% |
| EPS | 26.44 | 21.04 | 15.98 | 10.6 |
| % Growth | 25.7% | 31.7% | 50.8% | – |
| EPS Diluted | 24.64 | 19.81 | 15 | 10.06 |
| Weighted Avg Shares Out | 45 | 47 | 46 | 45 |
| Weighted Avg Shares Out Dil | 49 | 50 | 49 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $199 | $163 | $45 | $17 |
| Interest Expense | $43 | $59 | $32 | $19 |
| Depreciation & Amortization | $73 | $53 | $51 | $50 |
| EBITDA | $1,654 | $1,387 | $1,040 | $737 |
| % Margin | 57.5% | 59.6% | 53.7% | 43.7% |